DK2137192T3 - Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme - Google Patents
Derivater af galantamin som prodrugs til behandling af humane hjernesygdommeInfo
- Publication number
- DK2137192T3 DK2137192T3 DK08735211.8T DK08735211T DK2137192T3 DK 2137192 T3 DK2137192 T3 DK 2137192T3 DK 08735211 T DK08735211 T DK 08735211T DK 2137192 T3 DK2137192 T3 DK 2137192T3
- Authority
- DK
- Denmark
- Prior art keywords
- galantamine
- prodrugs
- derivatives
- treatment
- human brain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2008/002929 WO2009127218A1 (en) | 2008-04-14 | 2008-04-14 | Derivatives of galantamine as pro-drugs for the treatment of human brain diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2137192T3 true DK2137192T3 (da) | 2014-05-26 |
Family
ID=40019199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08735211.8T DK2137192T3 (da) | 2008-04-14 | 2008-04-14 | Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2137192B8 (da) |
JP (1) | JP5504253B2 (da) |
CN (1) | CN102007129B (da) |
CA (1) | CA2721007C (da) |
DK (1) | DK2137192T3 (da) |
ES (1) | ES2463715T3 (da) |
PL (1) | PL2137192T3 (da) |
WO (1) | WO2009127218A1 (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3417862B1 (en) * | 2012-07-27 | 2021-05-05 | Neurodyn Life Sciences Inc. | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
ES2880399T3 (es) | 2012-07-27 | 2021-11-24 | Neurodyn Life Sciences Inc | Biodisponibilidad cerebral mejorada de galantamina mediante formulaciones seleccionadas y administración transmucosa de profármacos lipofílicos |
WO2015148480A1 (en) | 2014-03-25 | 2015-10-01 | Emicipi Llc | Treatment of rett syndrome |
JP6796056B2 (ja) * | 2014-03-25 | 2020-12-02 | シナプテック・ディヴェロップメント・エルエルシーSynaptec Development Llc | 自閉症の治療 |
CA2949395C (en) * | 2014-05-16 | 2024-01-02 | Synaptec Development Llc | Clearance of amyloid.beta. |
EP4029867A1 (en) | 2021-01-13 | 2022-07-20 | Alpha Cognition Inc. | Solid forms of galantamine benzoate gluconate |
EP4186509A1 (en) | 2021-11-26 | 2023-05-31 | Alpha Cognition Inc. | Alpha-1062 for treating traumatic brain injury |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
WO1988008708A1 (en) | 1987-05-04 | 1988-11-17 | Bonnie Davis | Compounds for the treatment of alzheimer's disease |
US6323196B1 (en) | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
US6316439B1 (en) | 1993-10-15 | 2001-11-13 | Aventis Pharamaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
US6323195B1 (en) | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
AT403803B (de) | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
AU1282099A (en) * | 1997-10-29 | 1999-05-17 | Bonnie M. Davis | Method for treatment of disorders of attention |
WO2000032199A1 (de) | 1998-12-01 | 2000-06-08 | Sanochemia Pharmazeutika Aktiengesellschaft | Verwendung von galanthamin und galanthaminderivaten bei akuten funktionellen hirnschäden |
JP2003516947A (ja) | 1999-12-10 | 2003-05-20 | デイビス、ボニー | ニコチン様物質受容体のモジュレーターとしてのガランタミンおよびリコラミンの類似物 |
HUP0202233A3 (en) | 2000-03-31 | 2004-12-28 | Sanochemia Pharmazeutika Ag | Derivatives and analogues of galanthamin, their use, pharmaceutical compositions containing them and process for the preparation of them |
US20030162770A1 (en) | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
CA2540248C (en) | 2003-09-26 | 2010-12-07 | Scinopharm Taiwan, Ltd. | Resolution of a narwedine amide derivative |
AT414125B (de) | 2003-09-29 | 2006-09-15 | Sanochemia Pharmazeutika Ag | Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln |
EP1777222A1 (en) * | 2005-09-22 | 2007-04-25 | Galantos Pharma GmbH | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
-
2008
- 2008-04-14 PL PL08735211T patent/PL2137192T3/pl unknown
- 2008-04-14 JP JP2011504317A patent/JP5504253B2/ja not_active Expired - Fee Related
- 2008-04-14 EP EP08735211.8A patent/EP2137192B8/en active Active
- 2008-04-14 CA CA2721007A patent/CA2721007C/en active Active
- 2008-04-14 CN CN200880128608.5A patent/CN102007129B/zh active Active
- 2008-04-14 WO PCT/EP2008/002929 patent/WO2009127218A1/en active Application Filing
- 2008-04-14 DK DK08735211.8T patent/DK2137192T3/da active
- 2008-04-14 ES ES08735211.8T patent/ES2463715T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
EP2137192B8 (en) | 2014-06-11 |
CN102007129A (zh) | 2011-04-06 |
JP5504253B2 (ja) | 2014-05-28 |
JP2011516588A (ja) | 2011-05-26 |
PL2137192T3 (pl) | 2014-07-31 |
CN102007129B (zh) | 2014-05-07 |
EP2137192A1 (en) | 2009-12-30 |
EP2137192B1 (en) | 2014-02-19 |
ES2463715T3 (es) | 2014-05-29 |
CA2721007C (en) | 2014-04-29 |
CA2721007A1 (en) | 2009-10-22 |
WO2009127218A1 (en) | 2009-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
DK2381965T3 (da) | Modulation af præ-mrna under anvendelse af splejsningsmodulerende oligonukleotider som terapeutiske midler til behandling af sygdom | |
DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
DK2504005T3 (da) | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme | |
DK2300443T3 (da) | Triazolderivater, der er anvendelige til behandling af sygdomme | |
DK2285808T3 (da) | Spiroindolderivater til behandling af parasitsygdomme | |
DK2227257T3 (da) | Anordninger til minimal-invasiv ekstraokular afgivelse af stråling til den posteriore del af øjet | |
EP2367512A4 (en) | LASER PROCESSING OF PHOTOCAUTERIZATION OF CRYSTALLINE | |
DK2207550T3 (da) | Tetrahydroquinolinderivater til behandling af post-traumatiske stress-lidelser | |
DK2451796T3 (da) | Tofaanaloger til behandling af dermatologiske lidelser eller tilstande | |
BRPI0919920A2 (pt) | compostos para tratamento de doenças e desordens oftálmicas | |
BRPI0813516A2 (pt) | Tratamento de distúrbios proliferativos de células b | |
DK2440230T3 (da) | Behandlingsregimener til behandling af neurologisk sygdom | |
BRPI0812755A2 (pt) | Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas | |
DK2747763T3 (da) | (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser | |
DK2627345T3 (da) | Formuleringer til behandling af sygdomme i de øvre luftveje | |
DK2252317T3 (da) | Behandling af makuladegeneration | |
DK2148667T3 (da) | Anvendelse af cyclohexanhexolderivater til behandling af øjensygdomme | |
BRPI0915428A2 (pt) | derivados de benzoxazinona atuando como agonistas adrenorreceptor beta2 para o tratamento de distúrbios respiratórios | |
BRPI0816712A2 (pt) | terapia de intervalo para o tratamento de tinnitus | |
BRPI0917440A2 (pt) | composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho | |
DK2137192T3 (da) | Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme | |
DK2117565T3 (da) | Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme | |
DK1841433T3 (da) | Præparat til behandling af lidelser i centralnervesystemet | |
BRPI0917210A2 (pt) | exoterma controlada de formulações de cianocrilato |